Estrogen deficiency

What it is

Estrogen deficiency — also called hypoestrogenism or low estrogen — is a state in which the body produces insufficient estrogen to maintain normal physiological function, affecting an estimated 1.5 million Canadian women between ages 45 and 55 at any given time. Estrogen is not a single hormone but a family of three: estradiol (E2), the dominant form during reproductive years; estrone (E1), which becomes the primary circulating estrogen after menopause; and estriol (E3), produced mainly during pregnancy. Together they regulate the reproductive system, bone density, cardiovascular health, brain function, skin integrity, and mood.

The most common cause is the natural decline in ovarian function during perimenopause and menopause, with natural menopause occurring at an average age of 51 in Canada. Estrogen deficiency can also occur at any age in women with premature ovarian insufficiency (POI), hypothalamic suppression, or surgical removal of both ovaries. When deficiency begins before age 40, the health consequences are often greater because the body is deprived of estrogen for a longer period.

Causes and mechanism

Estrogen production depends on a hormonal cascade: the hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn drive the ovaries to produce estradiol. Disruption at any point in this chain can cause deficiency.

Cause	Typical age of onset	Mechanism
Natural menopause	~51	Progressive ovarian follicle depletion
Premature ovarian insufficiency (POI)	Under 40	Autoimmune, genetic, or idiopathic follicle loss
Surgical menopause (bilateral oophorectomy)	Any age	Immediate, complete cessation of ovarian estrogen
Hypothalamic amenorrhoea	Teens–40s	GnRH suppression from stress, low body weight, or excessive exercise
Chemotherapy or pelvic radiation	Any age	Direct ovarian damage
Hyperprolactinaemia	Any age	Elevated prolactin suppresses GnRH cascade
Male hypogonadism / aromatase deficiency	Any age	Reduced testosterone-to-estrogen conversion via aromatase

Men also require estrogen — produced mainly by aromatase conversion of testosterone — for bone health, brain function, and cardiovascular protection. Men with hypogonadism or the rare genetic condition aromatase deficiency can develop significant bone loss from low estrogen, and estrogen monitoring is relevant for men on testosterone therapy.

Symptoms and diagnosis

Symptoms reflect estrogen's roles across multiple body systems.

Vasomotor and neurological: hot flashes, night sweats, sleep disruption, brain fog, difficulty concentrating, irritability, anxiety, and low mood. Declining estrogen alters serotonin and dopamine signalling, which is why perimenopausal mood changes are common and why women with a prior history of depression are at higher risk during this transition.

Genitourinary syndrome of menopause (GSM): vaginal dryness, itching, dyspareunia (painful intercourse), urinary urgency, frequency, and recurrent urinary tract infections. GSM affects an estimated 50–70% of postmenopausal women but is frequently undertreated.

Long-term skeletal and cardiovascular effects: estrogen normally suppresses osteoclast activity; its loss accelerates bone resorption, increasing fracture risk. Osteoporosis Canada estimates that 1 in 3 Canadian women over 50 will experience an osteoporotic fracture. Estrogen deficiency also shifts lipid profiles unfavourably and is associated with increased cardiovascular risk.

Diagnosis typically involves:

1. Serum FSH: a level above 40 IU/L on two tests at least 4 weeks apart, combined with absent periods, confirms ovarian insufficiency.
2. Serum estradiol (E2): low or undetectable levels confirm the deficiency. Testing is available through LifeLabs and Dynacare across most provinces.
3. Clinical symptom assessment: guidelines from the Society of Obstetricians and Gynaecologists of Canada (SOGC) emphasize that symptom history is as important as laboratory values.
4. DEXA bone density scan: recommended for women with premature estrogen loss to assess skeletal impact.

Treatment options

Treatment aims to restore estrogen to a level that relieves symptoms and reduces long-term risk.

Systemic hormone therapy (HT): the most effective treatment for vasomotor symptoms and bone protection. Available as oral tablets, transdermal patches, gels, and sprays. Transdermal estrogen is generally preferred because it bypasses first-pass liver metabolism, carrying a lower venous thromboembolism risk than oral formulations. Women with an intact uterus require a progestogen alongside estrogen to prevent endometrial hyperplasia; micronised progesterone appears to carry a more favourable breast cancer risk profile than older synthetic progestogens.

Local vaginal estrogen: creams, rings, or pessaries deliver estrogen directly to genitourinary tissue with very low systemic absorption. Appropriate for GSM when systemic therapy is not desired or not indicated.

For POI and surgical menopause: the SOGC and Endocrine Society both recommend HT until at least the average age of natural menopause (~51) to protect bone density, cardiovascular health, and quality of life. Untreated surgical menopause before 45 is associated with significantly higher fracture and cardiovascular risk.

Non-hormonal options: SNRIs (venlafaxine, desvenlafaxine) and gabapentin provide modest vasomotor symptom relief. Ospemifene, a selective estrogen receptor modulator, is an oral option for dyspareunia when vaginal estrogen is not suitable. Weight-bearing exercise, adequate calcium (1,000–1,200 mg/day), and vitamin D (800–2,000 IU/day) support bone health regardless of HT use.

Canadian patients can discuss HT options with their family physician, a gynaecologist, or through virtual menopause care platforms such as Felix, Cleo, Maple, Phoenix, or others operating in their province.

When to see a clinician in Canada

Seek evaluation if hot flashes, night sweats, sleep disruption, vaginal dryness, or mood changes are affecting daily life. Also see a clinician if:

• You are under 40 with absent or very irregular periods — POI warrants prompt diagnosis and treatment to protect bone and cardiovascular health over the decades ahead.
• You have had both ovaries removed and have not yet discussed hormone replacement.
• You are approaching or have passed menopause and want to understand your options for symptom management and long-term health protection.
• You are a man on testosterone therapy and want to understand whether estrogen monitoring is appropriate.

The SOGC's Menopause: Consensus Statement and Health Canada–approved product monographs for HT products are useful reference points when discussing options with your clinician.

Limitations and open questions

Research is still emerging on several important questions. The optimal duration of HT use — particularly for women who begin treatment in their 40s with POI — has not been established by long-term randomised trials. The 2002 Women's Health Initiative study, which generated widespread concern about HT safety, used oral conjugated equine estrogen with medroxyprogesterone acetate in women averaging 63 years of age; its findings do not straightforwardly apply to younger women using transdermal estradiol with micronised progesterone, but direct head-to-head trial data remain limited. The relationship between estrogen deficiency and dementia risk is an active area of investigation, with some observational data suggesting a protective window early in menopause, but Health Canada has not issued guidance on HT for cognitive protection. The long-term cardiovascular effects of HT initiated in women with surgical menopause before age 45 also require further study. Individual risk assessment with a knowledgeable clinician remains the most reliable approach.